Psilocybin Safety: Risks and Contraindications in Clinical Research

As psilocybin moves through clinical trials globally, researchers have gathered a detailed picture of its safety profile. While often characterised in popular culture as physically benign, psilocybin carries specific acute psychological and physiological risks that require careful management. In controlled research, these risks are mitigated through strict participant screening and intensive monitoring. Understanding how clinical trials handle safety—specifically who they exclude and what adverse events they report—provides an evidence-based perspective on psilocybin's risk profile. This article explores the safety context of clinical research and is explicitly not medical advice. Psilocybin remains a Schedule 7 controlled substance in South Africa, meaning its use outside of approved research is illegal.

Acute Risks in the Research Setting

In clinical trials, psilocybin is generally well-tolerated physically, but it is not risk-free. Acute physiological effects commonly include modest increases in heart rate and blood pressure. These changes are typically transient, but they necessitate medical monitoring, particularly because severe cardiovascular events, though rare, remain a theoretical risk for vulnerable individuals.

The primary safety concerns in psilocybin research are psychological. Participants can experience acute anxiety, fear, paranoia, or what researchers term a 'challenging experience'. These episodes can involve intense emotional distress, disorientation, and transient psychosis-like symptoms. In rare instances, clinical trials have reported prolonged psychological distress requiring extended medical or psychiatric care. Because trials are highly controlled, these acute psychological reactions are managed immediately by trained therapists, preventing them from escalating into longer-term harm.

Exclusion Criteria and Contraindications

To minimise these risks, clinical trials employ rigorous exclusion criteria. Researchers generally screen out individuals with a personal or family history of psychotic disorders, such as schizophrenia. This is because classic psychedelics act on the serotonin system, which is implicated in psychosis, and there is a concern that psilocybin could trigger latent psychotic conditions in vulnerable individuals.

Similarly, individuals with bipolar disorder, particularly those not on mood stabilisers, are often excluded due to the risk of triggering manic episodes. People with severe cardiovascular disease are also screened out due to the physiological effects of the substance. Additionally, trials typically exclude individuals currently taking certain medications, particularly antidepressants that interact with the serotonin system, to avoid adverse drug interactions and to ensure the pharmacological data remains clear. Active suicidal ideation is another strict exclusion criterion in many trials, as the acute psychological distress of a challenging experience could exacerbate immediate self-harm risks.

The Role of Clinical Support

The safety record of psilocybin in modern clinical trials is largely attributable to the environment in which the substance is administered. Researchers emphasise 'set' (the participant's mindset and preparation) and 'setting' (the physical and social environment). Before a session, participants undergo extensive psychological preparation. During the session, they are monitored continuously in a calm, controlled room by trained therapists who can provide reassurance if anxiety arises.

After the acute effects subside, 'integration' sessions help participants process their experiences. This level of care is resource-intensive and fundamentally different from unregulated, recreational, or self-administered use. The low incidence of serious adverse events in trials reflects the safety of this highly supported clinical model, not necessarily the inherent safety of unsupervised consumption.

The South African Regulatory and Safety Context

In South Africa, psilocybin is classified as a Schedule 7 substance under the Medicines and Related Substances Act. For any clinical research to occur locally, it requires stringent oversight from the South African Health Products Regulatory Authority (SAHPRA) and ethics committees, adhering to the same rigorous safety standards seen internationally.

The safety data from global trials raises important policy questions for South Africa. If psilocybin eventually proves to have therapeutic value, the challenge for regulators and policymakers is balancing patient access with the need to prevent unregulated use, which lacks the screening and clinical support that make trials safe. The precedent set by the cannabis decriminalisation debate highlights how South African courts and policymakers must weigh evidence of medical utility against the realities of unregulated access, always prioritising public health and safety.